Aptar and i2c partner for nextgen propellant dispersible Respitab

Aptar Pharma gets exclusive option for i2c's Respitab tech

Photo iC2 video

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a leading service provider for the development of pharmaceutical formulations, today announced an exclusive partnership to co-develop and promote i2c’s patented pressurized metered dose inhaler (pMDI) technology, Respitab.

A press release dated October 21, 2021, says that as part of the agreement, Aptar Pharma, who is the market leader in pulmonary drug delivery device solutions for the management and treatment of asthma and chronic obstructive pulmonary disease (COPD), will evaluate the commercial applications for Respitab. This will be done in
particular, for new, lower global warming potential (GWP) propellants.

Respitab is a propellant dispersible tablet that eliminates the need for a complex mixing
process used in standard pMDI manufacturing. A patented, innovative platform which
enables the transition to the next generation of pMDIs for a range of active pharmaceutical ingredients (APIs) and combination products, Respitab is also a cost-effective approach for new chemical entity (NCE) and generic pMDI products, simplifying the manufacturing process for HFC 152a and other propellants.

Suitable for APIs with different physicochemical properties, Respitab has highly efficient
aerosol properties and dose uniformity characteristics. Respitab’s other advantages include reduced waste and API losses, as well as ease of scalability.

Howard Burnett, vice president Global Pulmonary Category, Aptar Pharma commented, “We are pleased to partner with i2c on this novel technology which brings many benefits to the filling of metered dose inhalers. This development further enhances Aptar Pharma’s industry- leading portfolio of devices, which, combined with our broad spectrum of Aptar Pharma Services, allows us to offer end-to-end support to our clients and partners.”

“We are excited by this partnership with Aptar Pharma which brings together substantial
synergies to provide a lower GWP product range to patients in the pMDI format, the most
popular inhaler type across the globe,” added Glyn Taylor, CSO of i2c Pharmaceutical


Please enter your comment!
Please enter your name here